Cerecor Inc (NASDAQ:CERC) Announces Three Big News Items

Cerecor Inc (NASDAQ:CERC)

Cerecor Inc (NASDAQ:CERC) shares are the subject of several different news stories and are marginally up at noon EST. Over 1.5 million shares have traded hands which is much higher than their 30-day, daily average of 823,000. Today the biotech company announced Q2 financials, a $25 million rights sale to its CERC-501 treatment, and the retirement of its CEO.

Cerecor Inc (NASDAQ:CERC)
One month stock price chart for CERC.

Cerecor Financials

Cerecor Inc (NASDAQ:CERC) reported a Q2 2017 net loss of (-$1.8) million, or (-$0.14) per share compared to a net loss of (-$3.5) million, or (-$0.41) per share, for the same period in 2016. Q2 2017 Research and development expenses decreased to $0.5 million, compared to $2.5 million for Q2 2016. This decrease was driven primarily by the completion of Cerecor’s Phase 2 clinical trials for CERC-301 and CERC-501 in late 2016. General and administrative expenses for Q2 2017 decreased to $1.4 million, versus $1.6 million for Q2 of 2016. This decrease was driven primarily by a reduction in overall operations due to Cerecor’s limited cash position. As of June 30, 2017, cash and cash equivalents were $5.5 million and current liabilities were $1.7 million.

Today Cerecor Inc (NASDAQ:CERC) also announced that it sold all of its rights to CERC-501 to Janssen Pharmaceuticals, Inc. for $25 million. $3.75 million of that sum was deposited into a 12-month escrow account to secure future indemnification obligations to Janssen, as well as a possible $20 million regulatory milestone payment.

CERC-501 is an oral kappa opioid receptor antagonist that Cerecor developed as an adjunctive treatment of major depressive disorder (“MDD”) and for substance use disorders. CERC-501 has been observed to have activity in animal models of depression, substance withdrawal and dependence, and has been generally well-tolerated in five human clinical trials.

Cerecor CEO News

Lastly, today Cerecor Inc (NASDAQ:CERC) announced the retirement of Dr. Uli Hacksell, Cerecor’s President and CEO, effective Monday, August 14, 2017. John Kaiser, Chief Business Officer, has been appointed Interim CEO. Cerecor’s Board of Directors has initiated a search for a permanent Chief Executive Officer. Dr. Hacksell will stay on as Chairman of Cerecor’s Board.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CERC and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Interpace Diagnostics Group Inc (NASDAQ:IDXG) Disappoints Market

Interpace Diagnostics Group Inc (NASDAQ:IDXG)

Interpace Diagnostics Group Inc (NASDAQ:IDXG) shares fell over 9% on Friday after the molecular-testing service announced Q2 financial results after trading hours on Thursday. Prior to the financial release, IDXG shares traded over $0.90 but the day after the market reviewed the company’s financial statement, shares traded just $0.02 above their 52-week low of $0.70 before ending the day at $0.80. Volume was heavy.

Interpace Diagnostics Group Inc (NASDAQ:IDXG)
One month stock price chart for IDXG

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) is a molecular diagnostics company that develops cancer testing processes that seek to replace the need for surgery to obtain a biopsy sample. Interpace specializes in analysis that can better inform treatment options available to the cancer patient. Currently their pipeline addresses thyroid, pancreatic, and other cancers. Interpace believes that the approach of identifying gene mutations at the molecular level can help healthcare professionals diagnose abnormalities, and their progression, without the expense and potential negative side-effects of surgery.

Interpace posted a (-$6.3) million operational loss for Q2, 2017. Year to date the operational loss was (-$4.4) million compared to (-$7.5) million for the same period ended June 30, 2016. Included in the Q2 operational loss is a (-$2.7) million Loss on Extinguishment of Debt and (-$4.3) million year to date in 2017. Net Revenue for Q2 2017 was $3.9 million, up 11% from Q2 2016, and for the six-month period was $7.3 million, up 7% from the same period in 2016.

Jack Stover, Interpace Diagnostics Group, Inc. (NASDAQ:IDXG)’s President & CEO, stated, “Our cash position is now in excess of $14 million and we increased our stockholders’ equity by over $29 million since year-end. We are now well positioned to leverage our commercial resources and further build out our platforms,” noted Stover. “Additionally, continuing to make reimbursement progress, such as getting coverage for our ThyGenX assay with CIGNA, one of the largest healthcare insurers in the US, further demonstrates the importance of our diagnostic tests to the marketplace,”

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) stock has lost over 81% YTD, and is down almost 70% for the year.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $IDXG and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Chiasma Inc (NASDAQ:CHMA) Stock Moved by FDA News

Chiasma Inc (NASDAQ:CHMA)

Chiasma Inc (NASDAQ:CHMA) shares were up over 32% on Friday despite having announced a loss in their Q2 2017 financial release. The market responded forcefully to the news that Chiasma reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of a new Phase 3 clinical trial for its octreotide capsules product candidate –  provisionally trade-named Mycapssa. Mycapssa is being developed for the maintenance therapy of adult patients with acromegaly, a hormonal disorder.

Chiasma Stock Chart:

Chiasma Inc (NASDAQ:CHMA)
One month stock price chart for CHMA

The agreed-upon study is designed to address the concerns previously raised in the FDA’s Complete Response Letter (CRL) and was reached through Special Protocol Assessment (SPA) with the FDA’s Division of Metabolism and Endocrinology Products. A Special Protocol Assessment (SPA) is a process by which an applicant and the FDA reach an agreement on the protocol design, endpoints and analysis of a Phase 3 clinical study prior to initiation, in order to determine if the study adequately addresses scientific and regulatory requirements for FDA approval.

The trial, referred to as “OPTIMAL”, is a randomized, double-blind, placebo-controlled, nine-month trial in 50 adult acromegaly patients (at least 20% of whom must be recruited from the United States). OPTIMAL utilizes levels of insulin-like growth factor, IGF-1, as the sole primary endpoint measure Chiasma Inc (NASDAQ:CHMA) believes the trial is adequately powered to assess maintenance of biochemical control with octreotide capsules compared to placebo in adult acromegaly patients who previously demonstrated biochemical control on somatostatin receptor ligand injections. The Company anticipates release of top-line data from this new Phase 3 clinical trial by the end of 2019.

For Q2 2017, Chiasma Inc (NASDAQ:CHMA) reported a net loss of (-$6.9) million, or (-$0.28) per share. In Q2 2016, Chiasma reported a net loss of (-$26.7) million, or (-$1.10) per share. Q2 R&D  expenses were $4.3 million versus $14.8 million for the same period in 2016. The decrease was primarily due to approximately $7.4 million of non-recurring API purchases and pre-commercial manufacturing validation activities in 2016. There were also reduced compensation-related costs. There was also a Q2 drop of $0.8 million in clinical trial costs compared with Q2 2016.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CHMA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Can Zosano Pharma Corp (NASDAQ:ZSAN) Stock Turn Around?

Zosano Pharma Corp (NASDAQ:ZSAN)

Zosano Pharma Corp (NASDAQ:ZSAN) stock lost almost 10% Friday after their Q2 financial results were released, continuing a downtrend that has persisted ever since the stock broke through support at $1.20 on August 3. Share volume was more than double the 30-day, daily average. Friday marked the ninth day in a row ZSAN stock dropped in value, but Zosano shares are still well above their 52-week low of $0.45.

Zosano stock price chart:

Zosano Pharma Corp (NASDAQ:ZSAN)
One month ZSAN stock price chart

About Zosano

Zosano Pharma Corp (NASDAQ:ZSAN) is a clinical stage biopharmaceutical company focused on providing novel delivery methods of therapeutics using their proprietary Adhesive Dermally-Applied Microarray, or ADAM technology.  Zosano recently announced positive results from their ZOTRIP study that assessed M207, the company’s proprietary formulation of zolmitriptan. M207 is being assessed as an acute migraine treatment. It was delivered through the company’s proprietary ADAM technology.

Zosano’s ADAM technology consists of titanium micro-projections coated with drug, and the company’s formulation of zolmitriptan.  The ADAM technology delivers the drug by allowing the drug to be absorbed into the microcapillary system of the skin.  In February 2017, Zosano announced statistically significant results from the ZOTRIP trial, which demonstrated that the 3.8mg dose of M207 met both co-primary endpoints, achieving pain freedom at 2 hours.

Zosano Pharma Corp (NASDAQ:ZSAN) reported a Q2 2017 (-$6.7) million net loss, or (-$0.17) per share on a basic and diluted basis, compared with a Q2 2016 (-$6.6) million net loss, or (-$0.54) per share on a basic and diluted basis. R&D expenses increased to $4.4 million from $4.3 million in Q2 2016. General and administrative expenses were $2.2 million – up from $2.0 million in Q2 2016.

Zosano Stock

At the end of February 2017, ZSAN stock was trading near $3.50 but has been in a strong downtrend since. Back in February, ZSAN stock benefitted from positive clinical trial results. However, the stock has spent a lot of time trading below the $2.00 level over the past two years despite being given a $4.00 consensus price target. Two analysts cover the company. One assigns ZSAN stock as a “Strong Buy” while the other rates the shares as a “Hold”. YTD, ZSAN shares have performed moderately well – up almost 9%. However for the year the stock is down over 42%.

A change in earnings or sales may likely lift the stock. In 2014 the per share loss was (-$2.78). That per share loss was smaller in each of the next two reporting years but was still at (-$2.17) for 2016. Sales have also been a major factor. No sales were reported for 2016 but, back in 2012, a sales number of over $11.6 million was reported.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ZSAN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) Stock Paying Off, for Short-Sellers

Synergy Pharmaceuticals Inc (NASDAQ:SGYP)

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) stock is continuing the slide that began on Tuesday after the company released their Q2 financials. This morning SGYP stock broke through the $3 level on volumes almost four times their normal average. Wednesday, Synergy posted a Q2 net loss of (-$73.9) million or (-$0.33) per share. Analysts were expecting a loss of only (-$0.25).

Synergy stock chart:

Synergy Pharmaceuticals Inc (NASDAQ:SGYP)
One month SGYP stock price chart

Trulance is Synergy Pharmaceuticals Inc (NASDAQ:SGYP)’s main sales generator. The drug addresses chronic idiopathic constipation and its sales performance exceeded projections. More than 12,600 TRULANCE prescriptions have been filled and total monthly prescription volume had an average increase of more than 182% month-over-month. At the end of the second quarter, more than half of new TRULANCE prescriptions filled since launch were coming from new patients not previously on a branded prescription treatment, and 45% were patients that converted from other branded prescription treatments.

Gary S. Jacob, Ph.D., Chairman and CEO of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) stated ““The first half of 2017 was a truly transformative period for Synergy, as we transitioned into a commercial organization and launched our first product, TRULANCE, in the U.S. for the treatment of adults with chronic idiopathic constipation (CIC). We are pleased with the execution of our commercial strategy, and the strong initial demand for TRULANCE, reinforcing the need for new treatment options for patients suffering from CIC. And we are making significant progress in ensuring broad access to TRULANCE, highlighted by a number of favorable early decisions from key national payers.”

Synergy Pharmaceuticals Numbers

Although their featured drug, TRULANCE, seems to be selling well in the market, investors have been selling off SGYP stock. YTD, SGYP shares are down around 50% and down over 33% for the year. Currently the shares are trading within 2.5% of their 52-week low of $2.91. No doubt some of the downward pressure on SGYP stock is the large percent of the float held by short-sellers – over 27%. Still, analysts have given SGYP stock a consensus target price of $10.89.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SGYP and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) Stock Continues Trend

Aralez Pharmaceuticals Inc (NASDAQ:ARLZ)

Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) stock plunged 12.50% in Thursday’s trading session as investors reacted to a disappointing second quarter earnings report. A net loss of (-$27.5) million compared to (-$17.5) million reported a year earlier appears to have spooked the market thus fuelling the sell-off wave.

One month Aralez stock chart:

Stock Performance

Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) stock is currently trading at all-time lows after disappointing Q2 earnings. The stock has  been on a strong downtrend since late last year.

The stock currently has a negative net margin of 133.92% and a negative return on equity of 66.74%. A number of analysts have already initiated coverage of the stock with the majority of them rating the stock as a ‘sell’. ValuEngine lowered its rating on the stock to a ‘strong sell’ from a ‘sell’.

Aralez Pipeline

Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) is a global specialty pharmaceutical focused on the delivery of meaningful products for improving patients’ lives. The company generates shareholder value by acquiring, developing and commercializing products in cardiovascular, pain and other specialty areas. Its lead products include Fibricor, Cambia Fiorinal, and Fiorinal C.

During the second quarter, Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) announced the commercial launch of Zontivity which is indicated for the treatment of peripheral artery disease in patients with a history of post-myocardial history. A team of 75 sales representative is currently marketing the drug

“We are also delighted with the strength of the early launch metrics for Zontivity® and are pleased that, within weeks of our national launch we have already reached all-time high prescription levels,” said CEO Adrian Adams.

Cost Saving Push

Aralez reported revenues of $27.6 million for the second quarter up from $12.6 million reported a year earlier. The cost of product revenue dropped to $2.9 million from $3.4 million because of $0.8 million in inventory step-up costs associated with the Tribute merger.

Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) restructuring is gaining traction as the company continues to explore ways of reducing its costs of operations. In the second quarter, the company reduced its U.S sales force by 32% having also implemented a cost savings program designed to preserve financial flexibility. The company exited Q2 with $55 million in cash and cash equivalent which it says is sufficient to finance operations over the next 12 months.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ARLZ and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Neothetics Inc (NASDAQ:NEOT) Tumbles To 52-Week Low

Neothetics Inc (NASDAQ:NEOT)

Shares of Neothetics Inc (NASDAQ:NEOT) tumbled 18.04% after the company reported second quarter financial results that fell short of Wall Street expectations. The selloff came on the clinical stage pharmaceutical company reporting a wider than expected second quarter net loss of (-$2.8) million compared to (-$2.7) million reported a year ago.

Neothetics Inc (NASDAQ:NEOT)
One month NEOT stock price chart

Stock Performance

Thursday’s sell off pushed Neothetics Inc (NASDAQ:NEOT) on the brink of its 52 week low of $0.30 as it continues to trade in a tight $0.30-$0.46 trading range. Neothetics sentiments turned sour early last month after the stock gapped lower from highs of $2.3 a share to current lows of $0.37 a share.

The stock continues to trade below its 20 days moving average having also tanked more than 60% below its 50-day moving average. The stock is currently trading at all-time lows having tanked from highs of $2.6 a share as of June.

The clinical stage pharmaceutical develops therapeutics for fat reduction and body contouring. Its lead product is LIPO-202, an injectable formulation for the reduction of localized fat deposits under the chin as well as for the deduction of central abdominal reduction.

The board of directors recently approved plans to initiate acquisitions as well as partnerships as part of an effort that seeks to expand Neothetics Inc. (NASDAQ:NEOT) footprint into new areas of growth. Pursuit of strategic alliance is also geared towards discovering and maximizing shareholder value. The company has already engaged the services of Oppenheimer and Co as its financial advisor for the new initiative.

Neothetics Inc (NASDAQ:NEOT) has also announced plans to streamline its operations as it seeks to preserve capital and cash resources. Plans are underway to trim the company’s workforce from six to two as the firm seeks to reduce its wage bill.

Q2 Earnings

The cost reduction drive follows an increase in research and development expenses in the second quarter to $1.6 million from $1.4 million. However, for the six months ended June 30, 2016, R&D expenditure dropped to $3.1 million from $4.7 million a year earlier. Neothetics attributes the decline to completion of a majority of close out activities for AbCONTOUR1 and AbCONTOUR2 U.S. Phase 3 clinical trials

Neothetics Inc (NASDAQ:NEOT) General and administrative expenses soared to $1.3 million from $1.1 million a year earlier. However, for the six months ended June 30, 2017, total general administrative expenses dropped to $2.7 million from $3.6 million a year earlier. The company attributes the decline to reduced personnel expenses.

Neothetics Inc. (NASDAQ:NEOT) exited the second quarter with cash and cash equivalent of $7.6 million compared to $11.5 million as of December 31, 2016.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $NEOT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Avinger Inc (NASDAQ:AVGR) Shares Drop on Revenue Concerns

Avinger Inc (NASDAQ:AVGR) Stock Tanks As Q2 Revenue Drops 47%

Avinger Inc (NASDAQ:AVGR) stock plunged 11.28% after the company reported second quarter financial results that fell short of Wall Street expectations. The company reported a net loss of $11.3 million, a disappointment compounded by a 47% decline in total revenue.

Wednesday’s sell-off of Avinger stock pushed it to near all-time lows as it continues to trade in a strong downtrend. Avinger stock continues to trade in a tight $0.40-$0.45 trading range and closing in on its 52-week lows of $0.35 a share.

Avinger stock, one-month price chart:

Avinger Inc (NASDAQ:AVGR)
One month chart for Avinger stock

Avinger Inc (NASDAQ:AVGR) is medical stage company that manufactures and sells image-guided and catheter-based systems for use in the treatment of peripheral arterial disease. The company also owns a proprietary lumivascular platform that integrates optical coherence tomography with catheters to provide real-time imaging during treatment.

Jeff Soinski, CEO, says they have made significant progress on the development of the next generation Pantheris Catheters. The next generation devices are expected to expand the company’s target market starting in 2018.

“Following our strategic reorganization in April, I’m pleased with how our more focused commercial organization has come together to drive utilization within our installed base of Lumivascular accounts,” said Mr. Soinski.

Avinger’s Disappointing Q2 Results

Total revenue in the second quarter came in at $2.5 million down by 47% compared to the second quarter of 2016. Gross margin dropped to -59% from 22% as of last year. Avinger Inc (NASDAQ:AVGR) attributes the decline to a $2.3 million charge for excesses and obsolete inventories.

In line with ongoing plans to reduce cash burn, Avinger Inc. successfully reduced its operating expenses to $9.8 million compared to $13.3 million as of Q2 2016. The decline was because of a decrease in sales and marketing expenditure this year compared to last year.

Avinger Inc (NASDAQ:AVGR) exited the second quarter with cash and cash equivalents of $14 million compared to $23 million as of March 31, 2017. Thanks to ongoing organizational restructuring, the company expects cash utilization to drop to $7 million per quarter compared to an average of 13.4 million per quarter as of last year.

Class Action Lawsuit

Separately, Avinger Inc (NASDAQ:AVGR) is the subject of a class-action lawsuit over claims its executives violated federal securities laws. Complaints allege that the Registration Statement and Prospectus filed for Avinger’s stock IPO contained false and misleading statements.

Law firms allege that Avinger failed to disclose that it did not have adequate marketing personnel for its lumivascular platform – a deficiency that has led to lackluster sales.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AVGR and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Novavax, Inc. (NASDAQ:NVAX) Stock Move Reflects Expectations

Novavax, Inc. (NASDAQ:NVAX)

Novavax, Inc. (NASDAQ:NVAX) stock price gained nearly 2% the day after the biotechnology company released their Q2 2017 financial results. Novavax reported a Q2 2017 quarterly loss of (-$44.5), on $6.7 million in revenue, or (-$0.16) per share. Results basically met street expectations. Novavax stock closed today at $0.99 on normal volume. Novavax stock price chart:

Novavax, Inc. (NASDAQ:NVAX)
One month stock price chart for NVAX

Gaithersburg, MD-based Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company that develops prducts, including vaccines, to prevent a broad range of infectious diseases. The company utilizes recombinant nanoparticles and Matrix-M™ adjuvant technology. Their product pipeline targets a variety of infectious diseases, with clinical vaccine candidates for respiratory syncytial virus (RSV) and Ebola virus (EBOV), and preclinical programs for Zika virus (ZIKV), seasonal influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates.

Novavax Financials

Research and development expenses decreased 40% to $39.3 million in the second quarter of 2017, compared to $64.9 million for the same period in 2016. The decrease was primarily due to reduced costs associated with the clinical trials and development activities of Novavax’s RSV F Vaccine and lower employee-related costs.

SG&A expenses decreased 37% to $8.9 million in Q2 2017, compared to $14.1 million for the same period in 2016. The decrease was primarily due to lower professional fees for pre-commercialization activities and lower employee-related costs.

Novavax stock has been a poor performer. YTD, Novavax shares have been down over 21% and are down over 86% for the year. Per share losses have been expanding ever since 2012 when Novavax posted a per share loss of (-$0.22). By 2016 that loss had broadened to (-$1.03). Likewise, dilution has been a real issue for stockholders. The number of outstanding shares has more than doubled since 2012 when the number was posted at 131.73 million. By 2016 that number was over 270 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $NVAX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

OpGen Inc (NASDAQ:OPGN) Stock Follows Trend

OpGen Inc (NASDAQ:OPGN)

OpGen Inc (NASDAQ:OPGN) stock was down $0.02 at the close of today’s trading as investors absorbed its Q2 financial report after yesterday’s market close. OpGen Inc (NASDAQ:OPGN) reported a Q2 (-$4.2) million net loss compared with $5.1 million for Q2 2016. Net loss for the six months ended June 30, 2017 was $9.2 million compared with $9.6 million for the six months ended June 30, 2016.

OpGen Inc (NASDAQ:OPGN)
One month OPGN Stock Price Chart

OpGen’s total Q2 revenue was $0.7 million compared with $1.2 million for Q2 2016. Total revenue for the six months ended June 30, 2017 was $1.5 million compared with $2.3 million for the six months ended June 30, 2016.

OpGen Inc (NASDAQ:OPGN) Q2 operating expenses were $4.9 million compared with $6.2 million for the same period in 2016. Operating expenses for the six months ended June 30, 2017 were $10.6 million compared with $11.8 million for the six months ended June 30, 2016.

Cash and cash equivalents were $0.2 million as of June 30, 2017 compared with $4.1 million as of December 31, 2016. Subsequent to the close of Q2, OpGen Inc (NASDAQ:OPGN)  raised net proceeds of $8.7 million in a public offering.

OpGen stock is sitting on its 52-week lows of $0.30. OpGen shares have lost over 72% YTD, and are down over 85% for the year. Dilution has been an issue for shareholders. In 2014 10.72 million shares were outstanding but by 2016 that number ballooned to 17.67 million. Sales did improve from 2015 when OpGen posted a sales figure of $3.2 million which was followed in 2016 by a figure of $4.0 million. Meanwhile, per share losses have been the norm. For 2016 each share lost (-$1.10).

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OPGN stock and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.